Compounds, their preparation and use
    7.
    发明授权
    Compounds, their preparation and use 失效
    化合物,其制备和用途

    公开(公告)号:US07968723B2

    公开(公告)日:2011-06-28

    申请号:US11579712

    申请日:2005-05-03

    IPC分类号: C07D213/00 A01N43/78

    摘要: Novel compounds of the general formula (I), in which the variables are as defined in claim 1, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ subtype, namely, type 1 diabetes, type 2 diabetes, dyslipidaemia, syndrome X (including the metabolic syndrome, i.e. impaired glucose tolerance, insulin resistance, hyper-triglyceridaemia and/or obesity), cardiovascular diseases (including atherosclerosis) and hypercholesterolaemia.

    摘要翻译: 通式(I)的新型化合物,其中变量如权利要求1所定义,这些化合物用作药物组合物,包含该化合物的药物组合物和使用这些化合物和组合物的治疗方法。 本发明化合物可用于治疗和/或预防由过氧化物酶体增殖物激活受体(PPAR)介导的病症,特别是PPARδ亚型,即1型糖尿病,2型糖尿病,血脂异常,综合征X(包括代谢综合征 即葡萄糖耐量受损,胰岛素抵抗,高甘油三酯血症和/或肥胖),心血管疾病(包括动脉粥样硬化)和高胆固醇血症。

    Novel compounds, their preparation and use
    8.
    发明申请
    Novel compounds, their preparation and use 失效
    新型化合物,其制备和用途

    公开(公告)号:US20090209588A1

    公开(公告)日:2009-08-20

    申请号:US11579712

    申请日:2005-05-03

    摘要: Novel compounds of the general formula (I), in which the variables are as defined in claim 1, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ subtype, namely, type 1 diabetes, type 2 diabetes, dyslipidaemia, syndrome X (including the metabolic syndrome, i.e. impaired glucose tolerance, insulin resistance, hyper-triglyceridaemia and/or obesity), cardiovascular diseases (including atherosclerosis) and hypercholesterolaemia.

    摘要翻译: 通式(I)的新型化合物,其中变量如权利要求1所定义,这些化合物用作药物组合物,包含该化合物的药物组合物和使用这些化合物和组合物的治疗方法。 本发明化合物可用于治疗和/或预防由过氧化物酶体增殖物激活受体(PPAR)介导的病症,特别是PPARδ型亚型,即1型糖尿病,2型糖尿病,血脂异常,X综合征(包括代谢综合征 即葡萄糖耐量受损,胰岛素抵抗,高甘油三酯血症和/或肥胖),心血管疾病(包括动脉粥样硬化)和高胆固醇血症。